Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: Structure/function studies towards the rational design of inhibitors

PLoS Pathogens

Volumn 8, Issue 1, 2012, Pages

  Buschiazzo, Alejandro ^a,b   Muiá, Romina ^c   Larrieux, Nicole ^a   Pitcovsky, Tamara ^c   Mucci, Juan ^c,d   Campetella, Oscar ^c,d  

^a INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^b INSTITUT PASTEUR   (France)

^c INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; GLYCOSIDASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SIALIDASE; TRANS SIALIDASE NEUTRALIZING MONOCLONAL ANTIBODY; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY LABELING; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BINDING SITE; CATALYSIS; CELL CULTURE; CELL INVASION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; HOST PARASITE INTERACTION; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE IDENTIFICATION; SIALYLATION; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMA RANGELI; TRYPOMASTIGOTE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; BINDING SITES; CHAGAS DISEASE; GLYCOPROTEINS; MICE; NEURAMINIDASE; PROTEIN STRUCTURE, QUATERNARY; TRYPANOSOMA CRUZI; VIRULENCE FACTORS;

MAMMALIA; PROTOZOA; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMA RANGELI;

EID: 84857496022     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002474     Document Type: Article

References (62)

1. Rassi A Jr, Rassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388-1402.
2. Minoprio P, Itohara S, Heusser C, Tonegawa S, Coutinho A, (1989) Immunobiology of murine T. cruzi infection: the predominance of parasite-nonspecific responses and the activation of TCRI T cells. Immunol Rev 112: 183-207.
3. Taliaferro WH, Pizzi T, (1955) Connective tissue reactions in normal and immunized mice to a reticulotropic strain of Trypanosoma cruzi. J Infect Dis 96: 199-226.
4. Savino W, (2006) The thymus is a common target organ in infectious diseases. PLoS Pathog 2: e62.
5. Tribulatti MV, Mucci J, Van Rooijen N, Leguizamón MS, Campetella O, (2005) The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents. Infect Immun 73: 201-207.
6. de Titto EH, Araujo FG, (1988) Serum neuraminidase activity and hematological alterations in acute human Chagas' disease. Clin Immunol Immunopathol 46: 157-161.
7. Schenkman RP, Vandekerckhove F, Schenkman S, (1993) Mammalian cell sialic acid enhances invasion by Trypanosoma cruzi. Infect Immun 61: 898-902.
8. Schenkman S, Jiang MS, Hart GW, Nussenzweig V, (1991) A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell 65: 1117-1125.
9. Tomlinson S, Pontes de Carvalho LC, Vandekerckhove F, Nussenzweig V, (1994) Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J Immunol 153: 3141-3147.
10. Pereira-Chioccola VL, Acosta-Serrano A, Correia de Almeida I, Ferguson MA, Souto-Padron T, et al. (2000) Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-alpha-galactosyl antibodies. J Cell Sci 113: 1299-1307.
11. Previato JO, Andrade AF, Pessolani MC, Mendonca-Previato L, (1985) Incorporation of sialic acid into Trypanosoma cruzi macromolecules. A proposal for a new metabolic route. Mol Biochem Parasitol 16: 85-96.
12. Rubin-de-Celis SS, Uemura H, Yoshida N, Schenkman S, (2006) Expression of trypomastigote trans-sialidase in metacyclic forms of Trypanosoma cruzi increases parasite escape from its parasitophorous vacuole. Cell Microbiol 8: 1888-1898.
13. Agusti R, Couto AS, Campetella OE, Frasch AC, de Lederkremer RM, (1997) The trans-sialidase of Trypanosoma cruzi is anchored by two different lipids. Glycobiology 7: 731-735.
14. Alvarez P, Buscaglia CA, Campetella O, (2004) Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences. J Biol Chem 279: 3375-3381.
15. Leguizamón MS, Campetella O, Russomando G, Almiron M, Guillen I, et al. (1994) Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections. J Infect Dis 170: 1570-1574.
16. Leguizamón MS, Mocetti E, Garcia Rivello H, Argibay P, Campetella O, (1999) trans-sialidase from Trypanosoma cruzi induces apoptosis in cells from the immune system in vivo. J Infect Dis 180: 1398-1402.
17. Risso MG, Pitcovsky TA, Caccuri RL, Campetella O, Leguizamón MS, (2007) Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections. Parasitology 134: 503-510.
18. Mucci J, Hidalgo A, Mocetti E, Argibay PF, Leguizamón MS, et al. (2002) Thymocyte depletion in Trypanosoma cruzi infection is mediated by trans-sialidase-induced apoptosis on nurse cells complex. Proc Natl Acad Sci U S A 99: 3896-3901.
19. Chuenkova M, Pereira ME, (1995) Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease. J Exp Med 181: 1693-1703.
20. Risso MG, Garbarino GB, Mocetti E, Campetella O, González Cappa SM, et al. (2004) Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages. J Infect Dis 189: 2250-2259.
21. Munoz MJ, Murcia L, Segovia M, (2011) The urgent need to develop new drugs and tools for the treatment of Chagas disease. Expert Rev Anti Infect Ther 9: 5-7.
22. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I, (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A 105: 5022-5027.
23. Buschiazzo A, Tavares GA, Campetella O, Spinelli S, Cremona ML, et al. (2000) Structural basis of sialyltransferase activity in trypanosomal sialidases. Embo J 19: 16-24.
24. Buschiazzo A, Amaya MF, Cremona ML, Frasch AC, Alzari PM, (2002) The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol Cell 10: 757-768.
25. Neres J, Brewer ML, Ratier L, Botti H, Buschiazzo A, et al. (2009) Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorg Med Chem Lett 19: 589-596.
26. Neres J, Bryce RA, Douglas KT, (2008) Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease. Drug Discov Today 13: 110-117.
27. Buchini S, Buschiazzo A, Withers SG, (2008) A new generation of specific Trypanosoma cruzi trans-sialidase inhibitors. Angew Chem Int Ed Engl 47: 2700-2703.
28. Pitcovsky TA, Buscaglia CA, Mucci J, Campetella O, (2002) A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase. J Infect Dis 186: 397-404.
29. Pitcovsky TA, Mucci J, Alvarez P, Leguizamón MS, Burrone O, et al. (2001) Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants. Infect Immun 69: 1869-1875.
30. Leguizamón MS, Russomando G, Luquetti A, Rassi A, Almiron M, et al. (1997) Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients. J Infect Dis 175: 1272-1275.
31. Campetella O, Sánchez DO, Cazzulo JJ, Frasch ACC, (1992) A superfamily of Trypanosoma cruzi surface antigens. Parasitol Today 8: 378-381.
32. Cremona ML, Campetella O, Sanchez DO, Frasch AC, (1999) Enzymically inactive members of the trans-sialidase family from Trypanosoma cruzi display beta-galactose binding activity. Glycobiology 9: 581-587.
33. Cremona ML, Sanchez DO, Frasch AC, Campetella O, (1995) A single tyrosine differentiates active and inactive Trypanosoma cruzi trans-sialidases. Gene 160: 123-128.
34. Watts AG, Damager I, Amaya ML, Buschiazzo A, Alzari P, et al. (2003) Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J Am Chem Soc 125: 7532-7533.
35. Buscaglia CA, Campetella O, Leguizamón MS, Frasch AC, (1998) The repetitive domain of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic domain. J Infect Dis 177: 431-436.
36. Powell LD, Hart GW, (1986) Quantitation of picomole levels of N-acetyl- and N-glycolylneuraminic acids by a HPLC-adaptation of the thiobarbituric acid assay. Anal Biochem 157: 179-185.
37. Muiá RP, Yu H, Prescher JA, Hellman U, Chen X, et al. (2010) Identification of glycoproteins targeted by Trypanosoma cruzi trans-sialidase, a virulence factor that disturbs lymphocyte glycosylation. Glycobiology 20: 833-842.
38. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, et al. (2004) Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr 60: 2210-2221.
39. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
40. Smart OS, Brandl M, Flensburg C, Keller P, Paciorek W, et al. (2008) Refinement with Local Structure Similarity Restraints (LSSR) Enables Exploitation of Information from Related Structures and Facilitates use of NCS. Abstr Annu Meet Am Crystallogr Assoc Abstract TP139.
41. Davies DR, Padlan EA, Sheriff S, (1990) Antibody-antigen complexes. Annu Rev Biochem 59: 439-473.
42. Lawrence MC, Colman PM, (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234: 946-950.
43. Mucci J, Risso MG, Leguizamón MS, Frasch AC, Campetella O, (2006) The trans-sialidase from Trypanosoma cruzi triggers apoptosis by target cell sialylation. Cell Microbiol 8: 1086-1095.
44. Webster RG, Reay PA, Laver WG, (1988) Protection against lethal influenza with neuraminidase. Virology 164: 230-237.
45. Stumpp MT, Binz HK, Amstutz P, (2008) DARPins: a new generation of protein therapeutics. Drug Discov Today 13: 695-701.
46. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
47. Natarajan A, DeNardo SJ, (2010) PEGylation of Antibody Fragments to Improve Pharmacodynamics and Pharmacokinetics. In: Kontermann R, Dübel S, editors. Antibody Engineering 2 ed. Heidelberg Springer.
48. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, et al. (2006) An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J Mol Biol 356: 651-663.
49. Tulip WR, Varghese JN, Laver WG, Webster RG, Colman PM, (1992) Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J Mol Biol 227: 122-148.
50. Tulip WR, Varghese JN, Webster RG, Laver WG, Colman PM, (1992) Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface. J Mol Biol 227: 149-159.
51. Malby RL, Tulip WR, Harley VR, McKimm-Breschkin JL, Laver WG, et al. (1994) The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 2: 733-746.
52. Gulati U, Hwang CC, Venkatramani L, Gulati S, Stray SJ, et al. (2002) Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol 76: 12274-12280.
53. Amaya MF, Buschiazzo A, Nguyen T, Alzari PM, (2003) The high resolution structures of free and inhibitor-bound Trypanosoma rangeli sialidase and its comparison with T. cruzi trans-sialidase. J Mol Biol 325: 773-784.
54. Cohen NC, (2007) Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Chem Biol Drug Des 70: 557-565.
55. Montagna G, Cremona ML, Paris G, Amaya MF, Buschiazzo A, et al. (2002) The trans-sialidase from the african trypanosome Trypanosoma brucei. Eur J Biochem 269: 2941-2950.
56. Buschiazzo A, Frasch AC, Campetella O, (1996) Medium scale production and purification to homogeneity of a recombinant trans-sialidase from Trypanosoma cruzi. Cell Mol Biol (Noisy-le-grand) 42: 703-710.
57. Frank FM, Petray PB, Cazorla SI, Munoz MC, Corral RS, et al. (2003) Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 22: 77-86.
58. Goding JW, (1996) Monoclonal antibodies: principles and practices. London Academic Press.
59. Leslie AGW, (1990) Molecular data processing. In: Moras D, Podjarny AD, Thierry JC, editors. Crystallographic computing New York Oxford University Press.
60. Collaborative Computational Project N (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
61. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
62. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12-21.